Lectrona logo Boehringer Ingelheim
Funding Opportunities for
Scientific Advancement Grants (SAG)

Scientific Advancement Grants (SAG)

Boehringer Ingelheim is proud to support Scientific Advancement Grants that advance knowledge and understanding of basic, pre-clinical, outcomes and/or clinical science and to further scientific awareness and technologies for public health and welfare.

Boehringer Ingelheim may be involved to some extent in the creation of the materials or activities (e.g. consortia, providing suggestions or feedback) but cannot solely or disproportionately influence outcomes or hold the funding recipient accountable for achieving a specific outcome, and the funding recipient must retain ultimate control of the goals, activities, and any messaging or dissemination of knowledge.

SAGs may include third party research award programs (e.g., a professional society selected young investigator pre-clinical research grant), external research collaborations or external coalitions in which an activity or project is undertaken by Boehringer Ingelheim along with one or more external organizations (either for-profit or not-for-profit) that advances specific and discrete shared policy or disease awareness objectives.

Biosimilars/CNS/Immunology

Biosimilars

Fostering ongoing clinician and patient education through collaborative initiatives including (but not limited to) scientific research, medical roundtable discussions and working groups for chronic auto-immune diseases.

CNS

Fostering ongoing clinician and patient central nervous system disease state education through collaborative initiatives including (but not limited to) scientific research, medical roundtable discussions and working groups.

Immunology

Fostering ongoing clinician and patient immune-mediated disease state education through collaborative initiatives including (but not limited to) scientific research, medical roundtable discussions and working groups.

Cardiometabolism

Cardiometabolism

Foster ongoing cardio-renal-metabolism disease education for the clinician through collaborative initiatives including (but not limited to) scientific research, medical roundtable discussions and working groups.

Oncology

Oncology

Support scientific or patient initiatives in Oncology that seek to improve the understanding of disease, patient care, or more broadly serve to elevate oncology medical practice through basic research, round table discussions, education and working groups.

Respiratory

Chronic Obstructive Pulmonary Disease (COPD)

Fostering ongoing clinician and patient disease state education through collaborative initiatives including (but not limited to) scientific research, medical roundtable discussions and working groups for Chronic Obstructive Pulmonary Disease (COPD).

Interstitial Lung Disease

Fostering ongoing Interstitial Lung Disease (ILD) clinician and patient disease state education through collaborative initiatives including (but not limited to) scientific research, medical roundtable discussions and working groups.

Cardiovascular

(Currently, proposals are not being accepted in this area at this time)

Back to Medical Education Grant Overview

During the COVID-19 outbreak, patient, community and health care provider safety and wellbeing remains the highest priority for Boehringer Ingelheim Pharmaceuticals, Inc. ("BIPI").

The COVID-19 situation is changing on a daily basis across the world, which results in operational challenges; timelines and program-format modifications (i.e. live to virtual). It is our intent to be as flexible as reasonably possible with timelines as they pertain to start and end dates, program format, reports and other affected obligations, as stated in the agreement.

If a change of scope (COS) request is needed for an approved grant, please reach out to your BIPI Medical Education Personnel (MEP) to initiate the request within our Global Funding System.

For all payment, reconciliation, spend reporting questions or concerns; please reach out to our service mailbox at MEDSCICOMMOps.US@boehringer-ingelheim.com.

BIPI will evaluate every grant impacted on a case-by-case basis.

It is highly encouraged that any new grant submissions with a start date prior to September 1, 2020, only include virtual or print components.

Any grants after the start date of September 1, 2020, can include live activities.

We wish you, your staff and your family good health.